Accepted for Publication: September 3, 2014.
Published Online: January 12, 2015. doi:10.1001/jamaneurol.2014.3314.
Study concept and design: Fleisher, Quiroz, Jakimovich, Langbaum, Lopera, Reiman.
Acquisition, analysis, or interpretation of data: Fleisher, Chen, Quiroz, Jakimovich, Gutierrez Gomez, Langois, Roontiva, Lee, Ayutyanont, Moreno, Muñoz, Tirado, Acosta-Baena, Fagan, Giraldo, Garcia, Huentelman, Tariot, Lopera, Reiman.
Drafting of the manuscript: Fleisher, Chen, Quiroz, Jakimovich, Gutierrez Gomez, Langois, Roontiva, Lee, Ayutyanont, Lopez, Moreno, Muñoz, Tirado, Acosta-Baena, Fagan, Giraldo, Garcia, Huentelman, Tariot, Lopera, Reiman.
Critical revision of the manuscript for important intellectual content: Fleisher, Chen, Lopera, Reiman.
Statistical analysis: Chen, Roontiva, Lee, Acosta-Baena, Tariot.
Obtained funding: Fleisher, Tariot, Reiman.
Administrative, technical, or material support: Fleisher, Chen, Roontiva, Thiyyagura, Lee, Ayutyanont.
Study supervision: Fleisher, Lopera, Reiman.
Conflict of Interest Disclosures: Dr Fleisher reported serving as a consultant for Eli Lilly and Company, Avid Radiopharmaceuticals, Merck and Company, Grifols, Quintiles, and Biogen; serving as an invited speaker for Quintiles, Avid Radiopharmaceuticals, and Eli Lilly and Company continuing medical education grant programs; being a member of the data and safety monitoring board for the National Institute on Aging, Merck and Company, and Pfizer; receiving grant funding from the National Institute on Aging and Eli Lilly and Company; and performing studies sponsored by Merck and Company, Roche, Genentech, Pfizer, Avanir, Takeda, Eli Lilly and Company, Bristol-Myers Squibb, Baxter, Neuroptix, and Wyeth. Dr Tariot reported receiving consulting fees from Abbott Laboratories, AbbVie, AC Immune, Boehringer-Ingelheim, California Pacific Medical Center, Chase Pharmaceuticals, CME Inc, Medavante, Otsuka, Sanofi-Aventis, Eli Lilly and Company, AstraZeneca, Avanir, Bristol-Myers Squibb, Cognoptix, Janssen, Merck and Company, and Roche; receiving research support from AstraZeneca, Avanir, Bristol-Myers Squibb, Cognoptix, Janssen, Merck and Company, Roche, Baxter, Functional Neuromodulation Ltd, GE Healthcare, Genentech, Pfizer, Targacept, Avid Radiopharmaceuticals, the National Institute on Aging, and the Arizona Department of Health Services; having stock options in Adamas Pharmaceuticals; and contributing to a patent for biomarkers of Alzheimer disease owned by the University of Rochester. Dr Reiman reported receiving research funding from Avid Radiopharmaceuticals and serving as a paid consultant for Eli Lilly and Company. No other disclosures were reported.
Funding/Support:18F-florbetapir positron emission tomography data were acquired with financial support from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly and Company) as noted in our group’s previous study.5 This study was supported by the FIL Foundation, Banner Alzheimer’s Foundation, Avid Radiopharmaceuticals, Nomis Foundation, Forget Me Not Initiative, Colciencias, grant 111554531651 from the Universidad de Antioquia, and grants R01 AG031581, P30 AG19610, U19 AG03243806, RF1 AG041705, and R01 AG041232 from the National Institute on Aging and the State of Arizona.
Role of the Funder/Sponsor: This study was designed and conducted by investigators from the Banner Alzheimer’s Institute and Universidad de Antioquia. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Sergio Alvarez, MD, Andres Arbelaez, MD, Feliza Restrepo, MD, and their colleagues from the Hospital Pablo Tobón Uribe and Universidad de Antioquia, as well as Dan Bandy, MS, Hillary Protas, PhD, Stephanie Parks, BS, Xiaofen Liu, MS, and Ji Luo MS, from the Banner Alzheimer’s Institute, assisted in data management and collection. Aarti Shah, MS, of the Dominantly Inherited Alzheimer Network Biomarker Core at Washington University in St Louis performed cerebrospinal fluid and plasma biomarker analyses. Paul Thompson, PhD, and his colleagues provided the software used to generate the cortical surface maps in Figure 2. We thank our valued research participants and other members of the PSEN1 E280A mutation kindred for their invaluable dedication and inspiration.